Lilly Asia Ventures
Sean Zhang, Ph.D. is a Vice President at Lilly Asia Ventures (LAV). Prior to joining LAV, he was a management consultant at McKinsey's Silicon Valley office, focused on strategic consulting for biotech, pharma and medtech companies. Prior to McKinsey, Sean worked in business development and research at Allele biotech in San Diego. Sean completed his Postdoc research at UC San Diego in neuroscience and ophthalmology, and he holds Ph.D. in molecular biology from the University of Pittsburgh School of Medicine and B.S. in Bioengineering from Xi’an Jiaotong University.
This person is not in any offices
Lilly Asia Ventures
Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm, with offices in Shanghai, Hong Kong, and Palo Alto. Originated in 2008 as a corporate venture subsidiary of Eli Lilly, they spun off and became an independent investment management company. As one of the earliest biomedical venture investors in China, they have been consistently investing in the region for over a decade, and have recently increased our footprint in the U.S. Our team of over 30 distinguished scientific, medical, investment, and operational professionals embrace a culture of integrity, entrepreneurship, and team work. Currently, they manage over $1.2 billion of committed capital.